OBI Pharma (ROCO:4174) Interest Expense: NT$-13.13 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4174 OBI Pharma Inc ROCO:4174
44 GF Score
Price NT$28.25
GF Value NT$138.95
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is OBI Pharma Interest Expense?

OBI Pharma ROCO:4174 +1.99% 44 Interest Expense is NT$-13.13 Mil as of Dec. 2025. GuruFocus rates ROCO:4174 with a GF Score™ of 44/100 and a GF Value™ of NT$138.95 (Possible Value Trap). The stock has 9 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. OBI Pharma's interest expense for the three months ended in Dec. 2025 was NT$ -3.05 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-13.13 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. OBI Pharma's Operating Income for the three months ended in Dec. 2025 was NT$ -480.23 Mil. OBI Pharma's Interest Expense for the three months ended in Dec. 2025 was NT$ -3.05 Mil. OBI Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OBI Pharma  (ROCO:4174) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

OBI Pharma's Interest Expense for the three months ended in Dec. 2025 was NT$-3.05 Mil. Its Operating Income for the three months ended in Dec. 2025 was NT$-480.23 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2025 was NT$339.44 Mil.

OBI Pharma's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

OBI Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

OBI Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for OBI Pharma's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OBI Pharma Interest Expense Chart

OBI Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.80 -3.99 -7.94 -10.65 -13.13

OBI Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.79 -2.73 -4.21 -3.15 -3.05
ROCO:4174
44GF Score
OBI Pharma Inc ROCO:4174
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OBI Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-13.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of NT$-13.13 Mil mean?
OBI Pharma (ROCO:4174) has a Interest Expense of NT$-13.13 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on OBI Pharma and its competitors.
Is OBI Pharma's Interest Expense too high?
OBI Pharma's current Interest Expense is NT$-13.13 Mil. Overall, OBI Pharma has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does OBI Pharma's Interest Expense compare to VRTX and REGN?
OBI Pharma's Interest Expense of NT$-13.13 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on OBI Pharma and its competitors. OBI Pharma's current Interest Expense is NT$-13.13 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OBI Pharma stock overvalued right now?
Based on GuruFocus' analysis, OBI Pharma (ROCO:4174) is currently considered Possible Value Trap. The stock's GF Value™ is NT$138.95, compared to a current price of NT$28.25 — trading 79.7% below its estimated fair value. The current Interest Expense is NT$-13.13 Mil. OBI Pharma's overall GF Score™ is 44/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For OBI Pharma (ROCO:4174), the current Interest Expense is NT$-13.13 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OBI Pharma (ROCO:4174) Overvalued in 2026?

Based on GuruFocus' analysis, OBI Pharma stock appears to be undervalued. The current stock price of NT$28.25 is trading 79.7% below its estimated GF Value™ of NT$138.95. GuruFocus considers OBI Pharma to be Possible Value Trap.

Key valuation signals for ROCO:4174:

  • Interest Expense: NT$-13.13 Mil
  • GF Value™: NT$138.95 vs. price of NT$28.25 (79.7% below fair value)
  • GF Score™: 44/100 with 9 warning signs

No single metric tells the full story. See the ROCO:4174 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OBI Pharma Business Description

Address Zhongxiao East Road, 6th Floor, No. 508, Section 7, Nangang District, Taipei, TWN, 115
OBI Pharma Inc is engaged in the research and development of novel therapeutic agents and biologics for patients with unmet medical needs. The company has three reportable segments: the anti-cancer new drug segment, the botulinum toxin new drug segment, and the CDMO segment. Geographically, it generates the majority of its revenue from Taiwan.
44GF Score

Get the complete analysis for ROCO:4174

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$28.25
Price
NT$138.95
GF Value